Premium
Assessment of a novel nanoparticle hyperthermia therapy in a murine model of osteosarcoma
Author(s) -
Tuohy Joanne L.,
Fogle Jonathan E.,
Meichner Kristina,
Borst Luke B.,
Petty Christopher S.,
Griffith Emily H.,
Osborne Jason A.,
Lascelles B. Duncan X.
Publication year - 2018
Publication title -
veterinary surgery
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.652
H-Index - 79
eISSN - 1532-950X
pISSN - 0161-3499
DOI - 10.1111/vsu.12959
Subject(s) - monocyte , medicine , ccr2 , hyperthermia , chemotaxis , osteosarcoma , cxc chemokine receptors , cancer research , hyperthermia therapy , chemokine , macrophage polarization , macrophage , cxcr4 , immunology , chemokine receptor , in vitro , receptor , inflammation , biology , biochemistry
Objective To evaluate the effects of nanoparticle hyperthermia therapy on monocyte function and tumor‐derived factors associated with macrophage polarization in a murine osteosarcoma model. Study design Experimental study. Animals Female C3H mice. Methods Peripheral blood monocyte cell surface phenotype, monocyte chemotaxis, tumor messenger RNA expression, and survival were compared among osteosarcoma (OS)‐bearing mice treated with nanoparticle hyperthermia therapy, OS‐bearing mice with osteomyelitis, OS‐bearing mice, vehicle control mice, and normal control mice. Results OS‐bearing mice with osteomyelitis had a higher proportion of “nonclassical” monocytes (Ly6C lo ) compared with all other experimental groups. There were alterations in monocyte expression of multiple chemokine receptors among experimental groups including CXCR2, CCR2, and CXCR4. Monocytes from OS‐bearing mice treated with hyperthermia therapy exhibited greater chemotaxis compared with monocytes from OS‐bearing mice with osteomyelitis. Conclusion OS likely induced alterations in monocyte phenotype and function. Nanoparticle hyperthermia therapy increased in vitro monocyte chemotaxis. Clinical impact Enhancing monocyte/macrophage function in dogs with OS may enhance antitumor immunity.